https://pharmadog.xyz/news/564371 pharmadog en 2026-10-19T17:27:04.000Z Theranos whistleblower says new film ‘You Can See Everything’ is art, not a documentary https://pharmadog.xyz/news/564327 pharmadog en 2026-10-19T17:03:24.000Z ESMO 2026 preview spotlights upcoming abstracts from Zai Lab, GSK and Merck https://pharmadog.xyz/news/564183 pharmadog en 2026-10-19T16:43:59.000Z EyePoint cuts half its staff and ends wet AMD trials after second Phase 3 failure, pivots to diabetic macular edema https://pharmadog.xyz/news/564223 pharmadog en 2026-10-19T16:27:00.000Z Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic porphyria https://pharmadog.xyz/news/564242 pharmadog en 2026-10-19T16:19:38.000Z FDA Grants Accelerated Approval for Jemperli Immunotherapy in Locally Advanced Rectal Cancer https://pharmadog.xyz/news/564035 pharmadog en 2026-10-19T15:43:35.000Z Arbitrators profit heavily from No Surprises Act disputes, raising concerns over health-care billing practices https://pharmadog.xyz/news/564015 pharmadog en 2026-10-19T15:17:26.000Z Merck KGaA to acquire Silence Therapeutics for $1.1 billion, gaining Phase 3 PV siRNA asset https://pharmadog.xyz/news/563991 pharmadog en 2026-10-19T15:05:39.000Z Gilead to launch Phase 3 trial of oral α4β7 inhibitor after promising Phase 2 ulcerative colitis results https://pharmadog.xyz/news/563992 pharmadog en 2026-10-19T15:01:30.000Z EyePoint's Phase 3 trial fails, prompting 53% staff cuts; Lilly signs China drug delivery partnership https://pharmadog.xyz/news/563867 pharmadog en 2026-10-19T14:58:31.000Z China proposes new limits on foreign biotech acquisitions to protect domestic drug development https://pharmadog.xyz/news/563847 pharmadog en 2026-10-19T14:30:28.000Z Roche signs $15 billion ADC partnership with China's Hansoh, offering $400 million upfront https://pharmadog.xyz/news/564224 pharmadog en 2026-10-19T13:59:52.000Z Merck KGaA to acquire Silence Therapeutics for $1.3 billion, adding Phase-2 RNAi drug for polycythemia vera https://pharmadog.xyz/news/563655 pharmadog en 2026-10-19T13:57:45.000Z Merck KGaA to acquire Silence Therapeutics for $1.3 billion, expanding siRNA portfolio https://pharmadog.xyz/news/563848 pharmadog en 2026-10-19T13:57:01.000Z China proposes ban on biotech platform sales but keeps licensing deals open https://pharmadog.xyz/news/563699 pharmadog en 2026-10-19T13:39:28.000Z Former GOP lawmakers warn that confusing vaccine messaging could hurt party's midterm prospects https://pharmadog.xyz/news/563700 pharmadog en 2026-10-19T13:23:58.000Z FDA forms new board to guide drug exclusivity decisions as Roche reexamines German investments https://pharmadog.xyz/news/563679 pharmadog en 2026-10-19T13:17:00.000Z Novartis halts Phase 2 lupus nephritis trial of Fabhalta, cites strategic reasons https://pharmadog.xyz/news/564055 pharmadog en 2026-10-19T13:14:00.000Z Roche signs up to $15 billion ADC partnership with China's Hansoh, paying $400 million upfront https://pharmadog.xyz/news/563656 pharmadog en 2026-10-19T13:00:41.000Z Sanofi partners with ScionxBio to screen long-acting RNA candidates https://pharmadog.xyz/news/563319 pharmadog en 2026-10-19T11:08:33.000Z Roche signs $400 million upfront deal with China's Hansoh, potential $15 billion partnership https://pharmadog.xyz/news/563343 pharmadog en 2026-10-19T11:02:00.000Z Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic protoporphyria, setting stage for FDA resubmission https://pharmadog.xyz/news/563344 pharmadog en 2026-10-19T11:01:00.000Z Veradermics reports Phase 3 minoxidil pill boosts hair coverage in men https://pharmadog.xyz/news/563211 pharmadog en 2026-10-19T11:00:36.000Z Disc Medicine's rare sun-sensitivity drug meets all endpoints in Phase 3 trial https://pharmadog.xyz/news/563212 pharmadog en 2026-10-19T11:00:09.000Z TriGemX Bio to go public via SPAC to advance migraine drug candidate https://pharmadog.xyz/news/563213 pharmadog en 2026-10-19T11:00:09.000Z Veradermics' oral minoxidil clears late-stage trial endpoints https://pharmadog.xyz/news/563798 pharmadog en 2026-10-19T10:46:00.000Z Eli Lilly teams with Hong Kong's Metis TechBio in up to $1.1 billion AI nanoparticle partnership https://pharmadog.xyz/news/563966 pharmadog en 2026-10-19T10:34:00.000Z TCGX uses SPAC to take migraine biotech TriGemX public, securing $246M for phase-3 trial https://pharmadog.xyz/news/563969 pharmadog en 2026-10-19T09:48:00.000Z Gilead reports positive Phase 2 results for oral ulcerative colitis drug https://pharmadog.xyz/news/563630 pharmadog en 2026-10-19T09:44:00.000Z Enlivex cuts 60% of staff, halts preclinical R&D and slashes exec salaries to fund osteoarthritis trial https://pharmadog.xyz/news/563631 pharmadog en 2026-10-19T09:00:00.000Z Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win https://pharmadog.xyz/news/562939 pharmadog en 2026-10-19T09:00:00.000Z Saudi Arabia rolls out biotech partnerships to support its $34.6 billion non‑oil growth plan https://pharmadog.xyz/news/562941 pharmadog en 2026-10-19T09:00:00.000Z Early CDMO engagement: balancing speed with flexibility in CMC planning https://pharmadog.xyz/news/562940 pharmadog en 2026-10-19T09:00:00.000Z Study shows low extractables in single-use components support ADC manufacturing https://pharmadog.xyz/news/562751 pharmadog en 2026-10-19T08:35:00.000Z Gilead’s oral ulcerative colitis drug shows significant remission in Phase 2 trial https://pharmadog.xyz/news/562754 pharmadog en 2026-10-19T08:30:00.000Z Editor shares personal loss and calls for assisted suicide options for severe mental illness https://pharmadog.xyz/news/562756 pharmadog en 2026-10-19T08:30:00.000Z Nonprofit arbitrators under No Surprises Act earning large profits, investigation finds https://pharmadog.xyz/news/562753 pharmadog en 2026-10-19T08:30:00.000Z Alphabet’s Isomorphic Labs draws VC interest as it seeks to turn AI protein modeling into drug discovery engine https://pharmadog.xyz/news/562752 pharmadog en 2026-10-19T08:30:00.000Z Immunology Society Split Over California’s $8.4 B Proposition 38 Funding Measure https://pharmadog.xyz/news/562755 pharmadog en 2026-10-19T08:30:00.000Z Measles resurgence threatens Republican midterm prospects, physicians warn https://pharmadog.xyz/news/563632 pharmadog en 2026-10-19T08:00:00.000Z Disc spins past FDA rejection with ‘overwhelmingly positive’ phase 3 data for rare disease drug https://pharmadog.xyz/news/563467 pharmadog en 2026-10-19T07:49:00.000Z Roche signs $15 billion ADC partnership with China's Hansoh Pharma https://pharmadog.xyz/news/562371 pharmadog en 2026-10-19T06:00:32.000Z Nouscom secures $135 million Series D to advance lead cancer vaccine into Phase 2 https://pharmadog.xyz/news/563018 pharmadog en 2026-10-19T05:16:00.000Z AbbVie’s combo of Skyrizi and trosunilimab shows higher remission than Skyrizi alone in phase 2 Crohn’s trial https://pharmadog.xyz/news/562119 pharmadog en 2026-10-19T05:00:00.000Z Sino Biological offers validated cytokines to improve organoid culture and research https://pharmadog.xyz/news/561951 pharmadog en 2026-10-19T04:18:00.000Z Merck/Moderna vaccine and Summit/Akeso bispecific therapy among key highlights at ESMO 2026 https://pharmadog.xyz/news/561952 pharmadog en 2026-10-19T04:02:00.000Z Experts tout amylin as promising, potentially gentler obesity target as new combo therapies near FDA review https://pharmadog.xyz/news/561953 pharmadog en 2026-10-19T04:01:00.000Z Multispecific drug design faces growing complexity as more binding arms increase molecular options https://pharmadog.xyz/news/563466 pharmadog en 2026-10-19T02:22:00.000Z Siemens Healthineers teams with Paradromics to develop multimodal imaging platform for brain-computer interfaces https://pharmadog.xyz/news/561299 pharmadog en 2026-10-19T00:54:03.000Z Cambridge biologist David Sabatini awarded $6 million after jury rejects harassment claims https://pharmadog.xyz/news/564149 pharmadog en 2026-10-18T08:23:00.000Z Labcorp to acquire BioReference Health assets for $722M cash